Onduarp

RSS

Withdrawn

This medicine's authorisation has been withdrawn

telmisartan / amlodipine
MedicineHumanWithdrawn

Italian is available via eTranslation, the European Commission's machine translation service.

Translate to Italian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 24 November 2011, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Onduarp, which combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor antagonist, telmisartan, and a dihydropyridinic calcium channel blocker, amlodipine.

The marketing authorisation holder (MAH) responsible for Onduarp was Boehringer Ingelheim International GmbH. On 17 February 2014, the European Commission issued a decision to withdraw the marketing authorisation for Onduarp, following its receipt of a letter dated 20 December 2013 notifying the Commission of the MAH’s decision to voluntarily withdraw the marketing authorisation for this product for commercial reasons. Onduarp was not marketed in any European country. 

Pursuant to this decision, the European public assessment report for Onduarp is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (630.81 KB - PDF)

Visualizza

español (ES) (540.23 KB - PDF)

Visualizza

čeština (CS) (592.53 KB - PDF)

Visualizza

dansk (DA) (576.08 KB - PDF)

Visualizza

Deutsch (DE) (544.29 KB - PDF)

Visualizza

eesti (ET) (523.65 KB - PDF)

Visualizza

ελληνικά (EL) (636.8 KB - PDF)

Visualizza

français (FR) (525.51 KB - PDF)

Visualizza

italiano (IT) (525.8 KB - PDF)

Visualizza

latviešu (LV) (599.49 KB - PDF)

Visualizza

lietuvių (LT) (554.08 KB - PDF)

Visualizza

magyar (HU) (583.99 KB - PDF)

Visualizza

Malti (MT) (593.57 KB - PDF)

Visualizza

Nederlands (NL) (523.66 KB - PDF)

Visualizza

polski (PL) (594.97 KB - PDF)

Visualizza

português (PT) (523.91 KB - PDF)

Visualizza

română (RO) (554.71 KB - PDF)

Visualizza

slovenčina (SK) (589.48 KB - PDF)

Visualizza

slovenščina (SL) (586.59 KB - PDF)

Visualizza

suomi (FI) (524.68 KB - PDF)

Visualizza

svenska (SV) (583.76 KB - PDF)

Visualizza

Product information

български (BG) (4.78 MB - PDF)

Visualizza

español (ES) (1.58 MB - PDF)

Visualizza

čeština (CS) (3.16 MB - PDF)

Visualizza

dansk (DA) (1.55 MB - PDF)

Visualizza

Deutsch (DE) (1.49 MB - PDF)

Visualizza

eesti (ET) (1.39 MB - PDF)

Visualizza

ελληνικά (EL) (5.04 MB - PDF)

Visualizza

français (FR) (1.5 MB - PDF)

Visualizza

hrvatski (HR) (1.1 MB - PDF)

Visualizza

italiano (IT) (1.46 MB - PDF)

Visualizza

latviešu (LV) (3.58 MB - PDF)

Visualizza

lietuvių (LT) (1.81 MB - PDF)

Visualizza

magyar (HU) (3.15 MB - PDF)

Visualizza

Malti (MT) (3.35 MB - PDF)

Visualizza

Nederlands (NL) (1.47 MB - PDF)

Visualizza

polski (PL) (3.44 MB - PDF)

Visualizza

português (PT) (1.47 MB - PDF)

Visualizza

română (RO) (1.87 MB - PDF)

Visualizza

slovenčina (SK) (3.3 MB - PDF)

Visualizza

slovenščina (SL) (3.26 MB - PDF)

Visualizza

suomi (FI) (1.53 MB - PDF)

Visualizza

svenska (SV) (1.43 MB - PDF)

Visualizza

Íslenska (IS) (561.49 KB - PDF)

Visualizza

norsk (NO) (580.92 KB - PDF)

Visualizza
Latest procedure affecting product information:WS/0236
17/02/2014
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (530.2 KB - PDF)

Visualizza

español (ES) (476.78 KB - PDF)

Visualizza

čeština (CS) (511.93 KB - PDF)

Visualizza

dansk (DA) (487.48 KB - PDF)

Visualizza

Deutsch (DE) (476.11 KB - PDF)

Visualizza

eesti (ET) (476.63 KB - PDF)

Visualizza

ελληνικά (EL) (536.96 KB - PDF)

Visualizza

français (FR) (487.46 KB - PDF)

Visualizza

italiano (IT) (474.03 KB - PDF)

Visualizza

latviešu (LV) (518.12 KB - PDF)

Visualizza

lietuvių (LT) (517.38 KB - PDF)

Visualizza

magyar (HU) (528.6 KB - PDF)

Visualizza

Malti (MT) (527.28 KB - PDF)

Visualizza

Nederlands (NL) (475.98 KB - PDF)

Visualizza

polski (PL) (507.57 KB - PDF)

Visualizza

português (PT) (487.82 KB - PDF)

Visualizza

română (RO) (515 KB - PDF)

Visualizza

slovenčina (SK) (512.76 KB - PDF)

Visualizza

slovenščina (SL) (499.61 KB - PDF)

Visualizza

suomi (FI) (487.61 KB - PDF)

Visualizza

svenska (SV) (476.49 KB - PDF)

Visualizza

Íslenska (IS) (25.81 KB - PDF)

Visualizza

norsk (NO) (19.76 KB - PDF)

Visualizza

Product details

Name of medicine
Onduarp
Active substance
telmisartan
International non-proprietary name (INN) or common name
  • telmisartan
  • amlodipine
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09DB04

Pharmacotherapeutic group

Cardiovascular system

Therapeutic indication

Treatment of essential hypertension in adults:

Add on therapy

Onduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.

Replacement therapy

Adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Onduarp containing the same component doses.

Authorisation details

EMA product number
EMEA/H/C/002118
Marketing authorisation holder
Boehringer Ingelheim International GmbH

Binger Strasse 173
D-55216 Ingelheim am Rhein
Germany

Marketing authorisation issued
24/11/2011
Withdrawal of marketing authorisation
17/02/2014
Revision
2

Assessment history

This page was last updated on

Share this page